The Journal of Clinical Pharmacology · 1986 · 45 citations · 14 references
PharmacyPharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyHemodynamic ManagementBlood Pressure ControlBlood Pressure ManagementDiuretic TherapyHypertension ControlHypertension ManagementHypertension PharmacotherapyAntihypertensive Drug TherapyAntihypertensive PharmacologyBlood PressureHypertensive Drug ResponseHypertensive Emergency ManagementPretreatmentRenin-angiotensin System InhibitorsRenin-angiotensin-aldosterone System Inhibitors
Enalaprilat (MK-422), an intravenously administered angiotensin-converting enzyme inhibitor, which is the parent compound of the oral angiotensin-converting enzyme inhibitor enalapril (MK-421), was studied in 11 patients with asymptomatic accelerated hypertension. Each patient received an initial intravenous dose of 1 mg, followed at one-hour intervals by enalaprilat 10 mg, furosemide 40 mg, and enalaprilat 40 mg. Six of 11 patients responded with a drop in mean arterial pressure greater than 15 mm Hg to diastolic levels below 110 mm Hg; there were four partial responders and one nonresponder. Pretreatment renins were not predictive of blood pressure response. No patient had any adverse reaction to the drug; there were no significant changes in posttreatment laboratory values. We conclude that enalaprilat is an effective, well-tolerated agent for the treatment of uncomplicated accelerated hypertension and its use does not imperil nonresponding uncomplicated patients.
14
A new class of angiotensin-converting enzyme inhibitors
Arthur A. Patchett, Elbert E. Harris, Edward W. Tristram et al. · Nature · 1980 · 706 citations